Resurrect Bio Lands €8.8M to Develop Resistant Crops

The big picture: Resurrect Bio, a London-based agricultural BioTech startup, has closed its oversubscribed Series A funding round at €8.8 million ($10.3 million). This final closing brings Resurrect Bio’s total funding to approximately $12.4 million since its 2022 inception, including a 2023 Seed round.

Why it matters:

• Sustainable Agriculture: Resurrect Bio provides a sustainable alternative to chemical crop protection by developing disease-resistant crops, reducing reliance on traditional pesticides.
• Food Security: Crop disease remains a significant challenge in global agriculture, and the company’s approach aims to boost yields and protect essential food sources.
• UK Plant Science Impact: The funding validates the potential of combining the UK’s plant science expertise with commercial ambition to create real-world agricultural solutions.

How it works:

• AI-Driven Discovery: Resurrect Bio utilizes its FloraFold® AI in silico discovery platform to predict interactions between plant and pathogen proteins, identifying potential resistance mechanisms.
• High-Throughput Validation: A high-throughput functional biology platform validates these AI-driven predictions at scale, accelerating the identification of viable resistance traits.
• Cryptic Resistance Reactivation: The company’s Resurrection platform reactivates cryptic resistance mechanisms already present in elite germplasm, compressing the timeline from discovery to deployment in crops.

The catch: While Resurrect Bio’s gene-editing and AI platforms offer a promising alternative to chemical crop protection, widespread adoption hinges on successful integration with existing seed company pipelines. The complex nature of gene-edited crops may also require navigating potential regulatory complexities and public perception challenges to achieve broad market acceptance.